MetaADEDB 2.0 @ LMMD
Clobetasol
(CBGUOGMQLZIXBE-XGQKBEPLSA-N)
Structure
SMILES
CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)C(=O)CCl
Type(s)
Approved
Molecular Formula:
C25H32ClFO5
Molecular Weight:
466.970
Log P:
4.1031
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
1
TPSA:
80.67
CAS Number(s):
25122-46-7
Synonym(s)
1.
Clobetasol
2.
Clobetasol 17-Propionate
3.
Clobetasol Propionate
4.
Clobex
5.
Clofenazon
6.
Cormax
7.
Dermovate
8.
Embeline
9.
Embeline E
10.
OLUX
11.
Temovate
12.
Clobetasol 17 Propionate
External Link(s)
MeSHD002990
PubChem Compound32798
BindingDB39347
ChEBI31414
CHEMBLCHEMBL1159650
DrugBankDB01013
DrugCentral4452
IUPHAR/BPS Guide to PHARMACOLOGY7062
KEGGdr:D01272
ZINC3977767
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 90US FAERS
2PruritusFAERS: 29US FAERS
3Burning sensationFAERS: 26US FAERS
4Incorrect drug administration durationFAERS: 26US FAERS
5ErythemaFAERS: 24OFFSIDES
US FAERS
6Application site painFAERS: 23US FAERS
7Product quality issueFAERS: 23US FAERS
8Wrong technique in product usage processFAERS: 21US FAERS
9Product use issueFAERS: 17US FAERS
10AlopeciaFAERS: 15US FAERS
11Inappropriate schedule of drug administrationFAERS: 15US FAERS
12PsoriasisFAERS: 15OFFSIDES
US FAERS
13Application site erythemaFAERS: 14US FAERS
14Accidental exposure to productFAERS: 13US FAERS
15Skin irritationFAERS: 13US FAERS
16Dry skinFAERS: 10US FAERS
17MalaiseFAERS: 10US FAERS
18PainFAERS: 10US FAERS
19No adverse eventFAERS: 9US FAERS
20OverdoseFAERS: 9US FAERS
21Product use in unapproved indicationFAERS: 9US FAERS
22Drug administration errorFAERS: 8US FAERS
23HeadacheFAERS: 8US FAERS
24Incorrect dose administeredFAERS: 8US FAERS
25Product container issueFAERS: 8US FAERS
26Squamous cell carcinomaFAERS: 8US FAERS
27Blood cortisol decreasedFAERS: 7US FAERS
28HypertrichosisFAERS: 7US FAERS
29Incorrect route of drug administrationFAERS: 7US FAERS
30Pharmaceutical product complaintFAERS: 7US FAERS
31DizzinessFAERS: 6US FAERS
32EcchymosisFAERS: 6US FAERS
33EczemaFAERS: 6US FAERS
34GangreneFAERS: 6US FAERS
35HypersensitivityFAERS: 6US FAERS
36Product physical consistency issueFAERS: 6US FAERS
37Vulvovaginal discomfortFAERS: 6US FAERS
38AcneFAERS: 5US FAERS
39Caustic injuryFAERS: 5US FAERS
40Drug ineffective for unapproved indicationFAERS: 5US FAERS
41Expired product administeredFAERS: 5US FAERS
42Exposure during breast feedingFAERS: 5US FAERS
43GlaucomaFAERS: 5US FAERS
44ObesityFAERS: 5US FAERS
45OverweightFAERS: 5US FAERS
46PurpuraFAERS: 5US FAERS
47AnxietyFAERS: 4US FAERS
48Application site pruritusFAERS: 4OFFSIDES
US FAERS
49Application site vesiclesFAERS: 4US FAERS
50ArthralgiaFAERS: 4US FAERS
51Aspartate Aminotransferase IncreasedFAERS: 4US FAERS
52Blood Corticotrophin DecreasedFAERS: 4US FAERS
53Cerebral atrophyFAERS: 4US FAERS
54Delayed myelinationFAERS: 4US FAERS
55Drug administered at inappropriate siteFAERS: 4OFFSIDES
US FAERS
56DysgeusiaFAERS: 4US FAERS
57Intentional drug misuseFAERS: 4US FAERS
58Intentional product misuseFAERS: 4US FAERS
59Intentional product use issueFAERS: 4US FAERS
60LipohypertrophyFAERS: 4US FAERS
61Low density lipoprotein increasedFAERS: 4US FAERS
62Product substitution issueFAERS: 4US FAERS
63Rash erythematousFAERS: 4US FAERS
64Steroid withdrawal syndromeFAERS: 4US FAERS
65Vulvovaginal erythemaFAERS: 4US FAERS
66Activities of daily living impairedFAERS: 3US FAERS
67Application site irritationFAERS: 3US FAERS
68AstheniaFAERS: 3US FAERS
69CataractFAERS: 3OFFSIDES
US FAERS
70Diabetes MellitusFAERS: 3US FAERS
71Drug abuseFAERS: 3US FAERS
72Drug effective for unapproved indicationFAERS: 3US FAERS
73DysuriaFAERS: 3OFFSIDES
US FAERS
74Eye irritationFAERS: 3US FAERS
75FatigueFAERS: 3OFFSIDES
US FAERS
76FolliculitisFAERS: 3US FAERS
77Growth retardationFAERS: 3US FAERS
78Incorrect product administration durationFAERS: 3US FAERS
79InflammationFAERS: 3US FAERS
80LethargyFAERS: 3US FAERS
81Mood swingsFAERS: 3US FAERS
82MyalgiaFAERS: 3US FAERS
83Pain of skinFAERS: 3US FAERS
84PalpitationsFAERS: 3US FAERS
85Peripheral swellingFAERS: 3US FAERS
86Product formulation issueFAERS: 3US FAERS
87Therapy non-responderFAERS: 3US FAERS
88Thermal burnFAERS: 3US FAERS
89VomitingFAERS: 3US FAERS
90Weight decreasedFAERS: 3US FAERS
91AbasiaFAERS: 2US FAERS
92Accidental exposure to product by childFAERS: 2US FAERS
93Accidental exposureFAERS: 2US FAERS
94Alanine Aminotransferase IncreasedFAERS: 2US FAERS
95Application site erosionFAERS: 2US FAERS
96BlindnessFAERS: 2US FAERS
97Blood urea increasedFAERS: 2US FAERS
98Chest discomfortFAERS: 2US FAERS
99Dermal absorption increasedFAERS: 2US FAERS
100DermatitisFAERS: 2US FAERS
101Dermo-hypodermitisFAERS: 2US FAERS
102DiscomfortFAERS: 2US FAERS
103Drug administered to patient of inappropriate ageFAERS: 2US FAERS
104Drug dispensing errorFAERS: 2US FAERS
105Drug effect delayedFAERS: 2US FAERS
106Drug effect incompleteFAERS: 2US FAERS
107Drug prescribing errorFAERS: 2US FAERS
108Drug withdrawal syndromeFAERS: 2US FAERS
109Ductus arteriosus premature closureFAERS: 2US FAERS
110Escherichia urinary tract infectionFAERS: 2US FAERS
111Expired drug administeredFAERS: 2US FAERS
112Fat redistributionFAERS: 2US FAERS
113Feeling abnormalFAERS: 2US FAERS
114HepatomegalyFAERS: 2US FAERS
115ImmunosuppressionFAERS: 2US FAERS
116IndurationFAERS: 2US FAERS
117Maternal exposure during pregnancyFAERS: 2US FAERS
118Medication ErrorFAERS: 2US FAERS
119Nerve injuryFAERS: 2US FAERS
120Night sweatsFAERS: 2US FAERS
121No reaction on previous exposure to drugFAERS: 2US FAERS
122Oral candidiasisFAERS: 2US FAERS
123OsteoporosisFAERS: 2OFFSIDES
US FAERS
124Poor feeding infantFAERS: 2US FAERS
125Product dispensing errorFAERS: 2US FAERS
126Product physical issueFAERS: 2US FAERS
127Product use complaintFAERS: 2US FAERS
128Rebound effectFAERS: 2US FAERS
129RestlessnessFAERS: 2US FAERS
130Septic ShockFAERS: 2US FAERS
131Skin UlcerFAERS: 2US FAERS
132Skin reactionFAERS: 2US FAERS
133SomnolenceFAERS: 2US FAERS
134SplenomegalyFAERS: 2US FAERS
135SunburnFAERS: 2US FAERS
136TachycardiaFAERS: 2US FAERS
137Urinary tract infectionFAERS: 2US FAERS
138UrticariaFAERS: 2US FAERS
139Visual ImpairmentFAERS: 2US FAERS
140Vulvovaginal burning sensationFAERS: 2US FAERS
141Abdominal PainFAERS: 1OFFSIDES
US FAERS
142Abdominal fat apronFAERS: 1US FAERS
143Abnormal weight gainFAERS: 1US FAERS
144AgeusiaFAERS: 1US FAERS
145AgitationFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
146AmnesiaFAERS: 1US FAERS
147AngerFAERS: 1US FAERS
148AnhidrosisFAERS: 1OFFSIDES
US FAERS
149AnorexiaFAERS: 1OFFSIDES
US FAERS
150AnosmiaFAERS: 1US FAERS
151Application site atrophyFAERS: 1US FAERS
152Application site burnFAERS: 1US FAERS
153Application site inflammationFAERS: 1US FAERS
154Application site pustulesFAERS: 1US FAERS
155Application site rashFAERS: 1US FAERS
156Application site reactionFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
157Application site scarFAERS: 1US FAERS
158Application site urticariaFAERS: 1US FAERS
159Atrial FibrillationFAERS: 1US FAERS
160Atrial FlutterFAERS: 1US FAERS
161Atrophic vulvovaginitisFAERS: 1US FAERS
162BedriddenFAERS: 1US FAERS
163BiopsyFAERS: 1US FAERS
164BlepharitisFAERS: 1US FAERS
165Blood chloride decreasedFAERS: 1US FAERS
166Blood cholesterol increasedFAERS: 1US FAERS
167Blood corticotrophin abnormalFAERS: 1US FAERS
168Blood creatinine decreasedFAERS: 1US FAERS
169Blood glucose increasedFAERS: 1US FAERS
170Blood immunoglobulin M increasedFAERS: 1US FAERS
171Blood triglycerides increasedFAERS: 1US FAERS
172Bone infarctionFAERS: 1US FAERS
173Borderline Personality DisorderFAERS: 1US FAERS
174Bowel movement irregularityFAERS: 1US FAERS
175CardiomegalyFAERS: 1US FAERS
176Chemical burn of skinFAERS: 1US FAERS
177ChokingFAERS: 1US FAERS
178Cortisol decreasedFAERS: 1US FAERS
179Cortisol free urine decreasedFAERS: 1US FAERS
180Culture urine positiveFAERS: 1US FAERS
181DeformityFAERS: 1US FAERS
182DehydrationFAERS: 1US FAERS
183Depressed moodFAERS: 1US FAERS
184Device defectiveFAERS: 1US FAERS
185Device malfunctionFAERS: 1US FAERS
186Diabetes mellitus inadequate controlFAERS: 1US FAERS
187DiplopiaFAERS: 1OFFSIDES
US FAERS
188Disease ProgressionFAERS: 1US FAERS
189Disease recurrenceFAERS: 1OFFSIDES
US FAERS
190Drug DependenceFAERS: 1US FAERS
191Drug dose omissionFAERS: 1US FAERS
192Drug exposure during pregnancyFAERS: 1OFFSIDES
US FAERS
193Ear discomfortFAERS: 1US FAERS
194Economic problemFAERS: 1US FAERS
195Eczema impetiginousFAERS: 1US FAERS
196Emotional distressFAERS: 1US FAERS
197EpistaxisFAERS: 1US FAERS
198ErysipelasFAERS: 1OFFSIDES
US FAERS
199Erythrodermic psoriasisFAERS: 1US FAERS
200Escherichia infectionFAERS: 1US FAERS
201Extra dose administeredFAERS: 1US FAERS
202Eyelid irritationFAERS: 1US FAERS
203Failure to ThriveFAERS: 1OFFSIDES
US FAERS
204FlushingFAERS: 1US FAERS
205FormicationFAERS: 1OFFSIDES
US FAERS
206Genital painFAERS: 1US FAERS
207Genital swellingFAERS: 1US FAERS
208Grip strength decreasedFAERS: 1US FAERS
209High density lipoprotein increasedFAERS: 1US FAERS
210HirsutismFAERS: 1US FAERS
211Hormone level abnormalFAERS: 1OFFSIDES
US FAERS
212Human herpesvirus 8 infectionFAERS: 1US FAERS
213HyperchlorhydriaFAERS: 1US FAERS
214HypotensionFAERS: 1US FAERS
215Hypothalamic pituitary adrenal axis suppressionFAERS: 1US FAERS
216Hypothalamo-pituitary disorderFAERS: 1US FAERS
217ImmobileFAERS: 1US FAERS
218ImpetigoFAERS: 1US FAERS
219Incorrect product dosage form administeredFAERS: 1US FAERS
220Incorrect route of product administrationFAERS: 1US FAERS
221InfectionFAERS: 1US FAERS
222Insurance issueFAERS: 1US FAERS
223LeukocytosisFAERS: 1US FAERS
224Lichen PlanusFAERS: 1US FAERS
225Lip swellingFAERS: 1US FAERS
226Lung consolidationFAERS: 1US FAERS
227LymphohistiocytosisFAERS: 1US FAERS
228Macular degenerationFAERS: 1US FAERS
229Medication residue presentFAERS: 1US FAERS
230Memory impairmentFAERS: 1US FAERS
231Mental impairmentFAERS: 1OFFSIDES
US FAERS
232Mental status changesFAERS: 1US FAERS
233MonoplegiaFAERS: 1US FAERS
234Musculoskeletal discomfortFAERS: 1US FAERS
235MyopathyFAERS: 1US FAERS
236Neck PainFAERS: 1US FAERS
237NoduleFAERS: 1OFFSIDES
US FAERS
238Oropharyngeal painFAERS: 1US FAERS
239Oropharyngeal swellingFAERS: 1US FAERS
240OsteopeniaFAERS: 1US FAERS
241PallorFAERS: 1US FAERS
242Penile InfectionFAERS: 1US FAERS
243Pericardial effusionFAERS: 1US FAERS
244Perivascular dermatitisFAERS: 1US FAERS
245PolyuriaFAERS: 1US FAERS
246Poor quality sleepFAERS: 1US FAERS
247Post inflammatory pigmentation changeFAERS: 1US FAERS
248Post-Traumatic Stress DisorderFAERS: 1US FAERS
249PregnancyFAERS: 1US FAERS
250Prescription drug used without a prescriptionFAERS: 1US FAERS
251Product adhesion issueFAERS: 1US FAERS
252Product administered to patient of inappropriate ageFAERS: 1US FAERS
253Product administration errorFAERS: 1US FAERS
254Product contamination physicalFAERS: 1US FAERS
255Product packaging issueFAERS: 1US FAERS
256Product packaging quantity issueFAERS: 1US FAERS
257Product prescribing errorFAERS: 1US FAERS
258Product prescribing issueFAERS: 1US FAERS
259PseudofolliculitisFAERS: 1US FAERS
260Purulent dischargeFAERS: 1US FAERS
261Pustular psoriasisFAERS: 1US FAERS
262RetchingFAERS: 1US FAERS
263RosaceaFAERS: 1US FAERS
264ScabFAERS: 1US FAERS
265Secretion dischargeFAERS: 1US FAERS
266Sexual DysfunctionFAERS: 1US FAERS
267Skin ErosionFAERS: 1US FAERS
268Skin discomfortFAERS: 1US FAERS
269Skin hypertrophyFAERS: 1US FAERS
270Skin lesionFAERS: 1US FAERS
271Swelling of eyelidFAERS: 1US FAERS
272SyncopeFAERS: 1US FAERS
273Therapeutic product cross-reactivityFAERS: 1US FAERS
274Therapeutic product effect delayedFAERS: 1US FAERS
275Therapeutic response unexpectedFAERS: 1US FAERS
276Therapeutic response unexpected with drug substitutionFAERS: 1US FAERS
277Thoracic vertebral fractureFAERS: 1US FAERS
278ThrombocytosisFAERS: 1US FAERS
279Tinea CapitisFAERS: 1US FAERS
280Tongue bitingFAERS: 1US FAERS
281Toxicity to various agentsFAERS: 1US FAERS
282TrichorrhexisFAERS: 1OFFSIDES
US FAERS
283Trichostasis spinulosaFAERS: 1US FAERS
284UlcerFAERS: 1US FAERS
285Unevaluable eventFAERS: 1US FAERS
286Urinary tract infection enterococcalFAERS: 1US FAERS
287Urine alcohol test positiveFAERS: 1US FAERS
288VIIth nerve paralysisFAERS: 1US FAERS
289Vulvovaginal painFAERS: 1US FAERS
290Vulvovaginal pruritusFAERS: 1US FAERS
291Vulvovaginal swellingFAERS: 1US FAERS
292Wrong technique in drug usage processFAERS: 1US FAERS
293XanthomaFAERS: 1US FAERS
294jaundiceFAERS: 1US FAERS
295Abdominal discomfortOFFSIDES
296Abdominal rigidityOFFSIDES
297Abnormal visionOFFSIDES
298AcanthosisOFFSIDES
299Acute myocardial infarctionOFFSIDES
300Acute respiratory failureOFFSIDES
301AdenocarcinomaOFFSIDES
302ApathyOFFSIDES
303ApneaOFFSIDES
304ArteriosclerosisOFFSIDES
305ArthritisOFFSIDES
306ArthropathyOFFSIDES
307AsthmaOFFSIDES
308AtelectasisOFFSIDES
309AutomatismOFFSIDES
310Back disorderOFFSIDES
311Blood amylase increasedOFFSIDES
312Blood cortisol increasedOFFSIDES
313Blood glucose decreasedOFFSIDES
314Blood lactate dehydrogenase increasedOFFSIDES
315Blood uric acidOFFSIDES
316Bone scan abnormalOFFSIDES
317BradycardiaOFFSIDES
318BronchiolitisOFFSIDES
319Bronchopulmonary DysplasiaOFFSIDES
320Bunion operationOFFSIDES
321BunionOFFSIDES
322Candidiasis of vaginaOFFSIDES
323Cell marker increasedOFFSIDES
324CellulitisOFFSIDES
325Cerebral artery occlusionOFFSIDES
326Cervicobrachial syndromeOFFSIDES
327Chest PainOFFSIDES
328Choking sensationOFFSIDES
329Chronic Obstructive Airway DiseaseOFFSIDES
330Compression fractureOFFSIDES
331Congenital tricuspid valve incompetenceOFFSIDES
332Cyst removalOFFSIDES
333DemyelinationOFFSIDES
334Device FailureOFFSIDES
335Device leakageOFFSIDES
336Device related infectionOFFSIDES
337DiabetesOFFSIDES
338Diabetic FootOFFSIDES
339DiarrheaOFFSIDES
340DiverticulumOFFSIDES
341DysmorphismOFFSIDES
342DyspareuniaOFFSIDES
343EnterocolitisOFFSIDES
344EpilepsyOFFSIDES
345Erythema MultiformeOFFSIDES
346Escherichia sepsisOFFSIDES
347Eye painOFFSIDES
348Face LiftOFFSIDES
349Facial wastingOFFSIDES
350Feelings of worthlessnessOFFSIDES
351GamblingOFFSIDES
352GoutOFFSIDES
353Granulocyte count decreasedOFFSIDES
354Head titubationOFFSIDES
355HomicideOFFSIDES
356HydrocephalusOFFSIDES
357HyperkeratosisOFFSIDES
358HypophagiaOFFSIDES
359Infective spondylitisOFFSIDES
360Intervertebral Disc DegenerationOFFSIDES
361Intestinal ObstructionOFFSIDES
362Leukopenia neonatalOFFSIDES
363Limb injuryOFFSIDES
364Loose toothOFFSIDES
365Lupus-like syndromeOFFSIDES
366LymphocytosisOFFSIDES
367MesotheliomaOFFSIDES
368Muscle necrosisOFFSIDES
369Musculoskeletal chest painOFFSIDES
370MyelodysplasiaOFFSIDES
371Nail InfectionOFFSIDES
372Nephrogenic Fibrosing DermopathyOFFSIDES
373Neutrophil count decreasedOFFSIDES
374OsteomyelitisOFFSIDES
375OsteosclerosisOFFSIDES
376Pancreatic enzymes increasedOFFSIDES
377PancreatitisOFFSIDES
378PeriodontitisOFFSIDES
379PeritonsillitisOFFSIDES
380PleurodesisOFFSIDES
381PneumothoraxOFFSIDES
382Psychiatric symptomOFFSIDES
383Pyoderma GangrenosumOFFSIDES
384Respiratory FailureOFFSIDES
385Retinopathy of PrematurityOFFSIDES
386SclerodermaOFFSIDES
387Sinus operationOFFSIDES
388SinusitisOFFSIDES
389Spinal column stenosisOFFSIDES
390Spinal fusion surgeryOFFSIDES
391SubileusOFFSIDES
392Synovial CystOFFSIDES
393Therapeutic product effect incompleteCanada Vigilance: 1Canada Vigilance
394TinnitusOFFSIDES
395Toe operationOFFSIDES
396Tooth ExtractionOFFSIDES
397Transaminases increasedOFFSIDES
398Trisomy 21OFFSIDES
399Urinary tract infection pseudomonalOFFSIDES
400Venous InsufficiencyOFFSIDES
401VertebroplastyOFFSIDES
402Violence-related symptomOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.